ReviewThe Lancet. Neurology2021
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.
Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph
Review in The Lancet. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06140511 (DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER), which is not on this map. Cited by 133 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 4 pooled it
17.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER: Constitution of a Cohort for a Long-term Prospective Follow-up Study
Who cites it
133 citing papers in PubMed, 4 syntheses or guidelines pooled it, 233 citations in OpenAlex.
- Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.Movement disorders : official journal of the Movement Disorder Society · 2025Pooled it
- Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies.Neuropsychology review · 2024Pooled it
- Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Pooled it
- Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.Translational neurodegeneration · 2022Pooled it
- Efficacy and Safety of Electroacupuncture on Insomnia in Parkinson's Disease: A Multicentre, Randomized, Controlled Trial.Movement disorders clinical practice · 2025Trial
- Trial
- Baseline characteristics of the North American prodromal Synucleinopathy cohort.Annals of clinical and translational neurology · 2023Trial
- Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum.Brain : a journal of neurology · 2026Article
- Sleep Disorders in Neurodegenerative Diseases: Pathological Correlations and Underlying Mechanisms.Neuroscience bulletin · 2026Review
- Multiple system atrophy: cure and care.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Advances in biomarkers for Parkinson's disease: from molecular pathology to precision diagnostics.Journal of Zhejiang University. Science. B · 2026Review
- Neuromelanin-sensitive MRI for identifying dopamine transporter imaging abnormality risk in idiopathic rapid eye movement sleep behavior disorder.Brain imaging and behavior · 2026Article
- Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.Brain, behavior, & immunity - health · 2026Article
- Large language model analysis of real-world phone calls reveals prodromal and progressive biomarker of parkinsonism: A two-year proof-of-concept study.PLOS digital health · 2026Article
- Characterization of patients with isolated REM sleep behavior disorder and cerebrospinal fluid α-synuclein negativity.NPJ Parkinson's disease · 2026Article
- Stage-specific polysomnographic and MRI markers across phenoconversion in isolated REM sleep behavior disorder.Journal of neurology · 2026Observational
- Spatio-temporal gait signatures across prodromal and early Parkinson's disease in two independent cohorts.Scientific reports · 2026Article
- Article
- Dream-enactment behaviors without REM sleep without atonia.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Article
- Association of wearable sensor-based gait analysis with phenoconversion trajectories in idiopathic REM sleep behavior disorder.NPJ Parkinson's disease · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors at 20 institutions in 14 countries.
Mitchell G MiglisDepartment of Neurology and Neurological Sciences and Department of Psychiatry and Behavioral Science, Stanford University, Palo Alto, CA, USA. Electronic address: mmiglis@stanford.edu.
Charles H AdlerDepartment of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
Elena AntelmiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Dario ArnaldiClinical Neurology, DINOGMI, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Luca BaldelliDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Bradley F BoeveDepartment of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA.
Matteo CesariDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Irene Dall'AntoniaDepartment of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
Nico J DiederichDepartment of Neuroscience, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.
Kathrin DopplerDepartment of Neurology, University of Würzburg, Würzburg, Germany.
Petr DušekDepartment of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
Raffaele FerriOasi Research Institute IRCCS, Troina, Italy.
Jean-François GagnonCentre for Advanced Research in Sleep Medicine, Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal-Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Ziv Gan-OrThe Neuro-Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, and Department of Human Genetics, McGill University, Montreal, QC, Canada.
Wiebke HermannDepartment of Neurology, University of Rostock, Rostock, Germany; German Center for Neurodegenerative Diseases (DZNE), Research Site Rostock, Rostock, Germany.
Birgit HöglDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Michele T HuNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Alex IranzoSleep Disorders Center, Neurology Service, Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona, Spain.
Annette JanzenDepartment of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany.
Anastasia KuzkinaDepartment of Neurology, University of Würzburg, Würzburg, Germany.
Jee-Young LeeDepartment of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
Klaus L LeendersDepartment of Nuclear Medicine and Biomedical Imaging, University Medical Center Groningen, Groningen, Netherlands.
Simon J G LewisForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
Claudio LiguoriSleep Medicine Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Jun LiuDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Christine LoNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Kaylena A Ehgoetz MartensDepartment of Kinesiology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, ON, Canada.
Jiri NepozitekDepartment of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
Giuseppe PlazziIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Federica ProviniDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; UOC Clinica Neurologica Rete Metropolitana NEUROMET, Bellaria Hospital, Bologna, Italy.
Monica PulighedduDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Michal RolinskiInstitute of Clinical Neurosciences, University of Bristol, Bristol, UK.
Jan RuszDepartment of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic.
Ambra StefaniDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Rebekah L S SummersDepartment of Neurology, University of Minnesota, Minneapolis, MN, USA.
Dallah YooDepartment of Neurology, Kyung Hee University Hospital, Seoul, South Korea.
Jennifer ZitserDepartment of Neurology and Neurological Sciences, University of California, San Francisco, CA, USA; Department of Neurology, Tel Aviv Sourasky Medical Center, Affiliate of Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Wolfgang H OertelDepartment of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, München-Neuherberg, Germany.
Charles University · CZInnsbruck Medical University · ATPhilipps University of Marburg · DEUniversity of Oxford · GBUniversity of Würzburg · DECentre Hospitalier de Luxembourg · LUCzech Technical University in Prague · CZGerman Center for Neurodegenerative Diseases · DEHôpital du Sacré-Cœur de Montréal · CAHospital Clínic de Barcelona · ESIstituto delle Scienze Neurologiche di Bologna · ITKyung Hee University · KRMayo Clinic · USMayo Clinic in Arizona · USMontreal Neurological Institute and Hospital · CAOasi Maria SS · ITOspedale Policlinico San Martino · ITSeoul National University · KRShanghai Jiao Tong University · CNStanford Medicine · US
Funding
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5MLongitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2MNeuroprotective Treatment Trial Planning in REM Sleep Behavior DisorderR34AG056639 · NIA · WASHINGTON UNIVERSITY · PI BOEVE, BRADLEY F, JU, YO-EL S · 2018 to 2019
$1.2MNCATS NIH HHS UL1 TR002494NIA NIH HHS P30 AG062677NIA NIH HHS R34 AG056639NINDS NIH HHS U01 NS100620
Abstract
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.
Indexed as
Biomarkersalpha-SynucleinDisease ProgressionHumansPrognosisREM Sleep Behavior DisorderSynucleinopathiesalpha-SynucleinBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06140511ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.